Dr. Ben Pless has been developing implantable medical devices for over 30 years and am an inventor on over 160 U.S. patents. His innovations include the detection of both cardiac and neural signals in developing FDA-approved devices to treat sudden cardiac death and epilepsy. He led the development of the NeuroPace neurostimulator, the only FDA-approved implanted device that monitors brain activity, diagnoses epileptiform activity, and automatically applies therapy to suppress seizures.
He is currently the President and CEO of Celero Systems, a company he founded to continue the development of ingestible monitoring and therapy delivery products based on intellectual property from Massachusetts General Hospital, Brigham and Women’s Hospital, and the Massachusetts Institute of Technology (MIT).
Prior to founding Celero Systems, He held numerous executive level positions in both established businesses (e.g., St. Jude Medical, now Abbott) and in start-up companies. Recently as the President and CEO of Autonomic Technologies, He recruited and led the team that developed the first trans-oral permanently implantable neurostimulator to target the sphenopalatine ganglion to treat severe headache.
He received a BSEE from MIT in Cambridge, MA and was a PhD candidate at Rice U in Houston, Texas.